News August 2022

3M Touts Easier NPWT With Instillation for Clinicians

The 3M Health Care Medical Solutions Division recently announced the release of the new 3M^™ Veraflo^™ Cleanse Choice Complete^™ Dressing Kit and a software upgrade for the 3M^™ V.A.C.^® Ulta Therapy Unit at no increase cost to the customer. The company notes these new offerings help simplify the care delivery processes for clinicians using Veraflo Therapy for negative pressure wound therapy (NPWT) with instillation. The new dressing kit also facilitates easier, faster, and less painful dressing changes for patients as compared to previous Veraflo Therapy dressings, says 3M. The device’s newly upgraded software, which includes the 3M^™ Smart Instill^™ Feature for use with Veraflo Therapy, automates therapy initiation and makes it easier for clinicians to initiate therapy, according to 3M. The company says additional upgraded functionalities include animated video troubleshooting, an instill phase postpone feature, a therapy inactive alarm time delay providing clinicians a choice to delay alarms during dressing changes, along with the updated default therapy settings.
 
The new default settings are based on the recommendations of a global panel of wound care leaders as outlined in a 2020 NPWT with instillation consensus guidelines update document published in the International Wound Journal, notes 3M.

Click here for more info.

New RCT: MolecuLight Fluorescence Imaging Improved 12-Week Wound Healing by 204% in DFUs 

MolecuLight Inc. recently announced the publication of an independent, blinded randomized controlled trial in Diabetes Care. The publication on this 56-patient trial, titled “The use of Point-of-Care Bacterial Autofluorescence Imaging in the Management of Diabetic Foot Ulcers: A Pilot Randomized Controlled Trial” reported that the use of a MolecuLight i:X^® device to visualize the presence of elevated bacterial burden in wounds doubled 12-week wound healing rates (204%) in diabetic foot ulcer (DFU) patients over standard-of-care alone.
 
Patients were stratified into two groups, one in which the MolecuLight device was not used, and one in which clinicians used the i:X biweekly to assess DFUs for the presence of elevated bacterial burden, notes the company. For the MolecuLight group, fluorescence imaging was performed after treatment. Fluorescence indicated the presence of elevated bacterial burden in over 80% of the wounds. In addition to the twofold improvement in healing rates, MolecuLight says this study showed an association between baseline fluorescence and wound outcomes. Of the patients with negative fluorescence images at the baseline visit, 53.9% healed at 12 weeks, versus 37.5% with positive baseline fluorescence images. The company adds that wound area reduction was superior in the MolecuLight arm and patient quality of life diverged toward improvement in the MolecuLight arm at 4 weeks and toward deterioration in the control arm at 12 weeks.

MolecuLight notes the Leeds (UK) Diabetes Limb Salvage service is now using the MolecuLight device to image all patients with wounds that are failing to achieve a healing trajectory within 4 weeks. To help manage patient volumes, patients who are negative with MolecuLight are triaged, and are then referred to community care as their wounds are considered manageable and able to achieve a healing trajectory.
 
Click here for more info.

BioTissue Co-Founder Recognized as Pioneer in Amniotic Membrane Technology Research for Ocular Surface Regeneration

BioTissue recently announced that research conducted by co-founder and Chief Technology Officer Scheffer C.G. Tseng, MD, PhD, has become the most cited laboratory investigation in the history of corneal research.

Dr. Tseng’s work in amniotic membrane regenerative medicine in ophthalmology and the interest it has drawn from the scientific community has led to it being cited in more than 1,300 publications, according to BioTissue. The impact of this groundbreaking research is recognized and celebrated by Kenneth R. Kenyon MD, Department of Ophthalmology, Tufts Medical Center, Tufts University School of Medicine, in a recent issue of Cornea Journal of Cornea and External Disease.

Laboratory-based research conducted by Dr. Tseng and his associates at the University of Miami demonstrated the potential for amniotic membrane to support corneal surface restoration. The company says his research has become globally recognized as having been the first of its kind to show how limbal stem cell transplantation with amniotic membrane can support ocular surface reconstruction for injuries such as chemical or thermal burns and ocular surface disease.

Click here for more info.